Press Release: Available for Immediate Release
The MPN Hub, run by Scientific Education Support (SES) in partnership with the European LeukemiaNet (ELN), has continued to promote significant developments in the research and treatment of myeloproliferative neoplasms (MPN) throughout Quarter 2 of 2021.
The MPN Hub is an open-access online resource dedicated to providing balanced, credible, and up-to-date medical education in MPN, and aims to enhance knowledge of MPN through the dissemination of advances related to their classification, diagnosis, treatment, and management via multiple channels.
Speaking about the hub’s activity, Mia Hill, IME director at Scientific Education Support, said:
“In May, the MPN Hub held its third steering committee meeting, which was again a great success owing to valued contributions from our steering committee members. June was particularly busy, with the MPN Hub covering both the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, held on June 4–8, 2021, and the European Hematology Association (EHA) 2021 Virtual Congress, held on June 9–17, 2021. We provided extensive live Twitter coverage, expert interviews across key clinical topics relating to MPN and tailored our written summary articles towards key talks from both conferences.”
The MPN Hub would like to thank its supporters—Bristol Myers Squibb, Novartis, AbbVie, Kartos Therapeutics, Roche Genentech, AOP Orphan, Geron, and Sierra Oncology—for their continued support of the platform.
For more information on the MPN Hub, please visit mpn-hub.com.
For media enquiries or to explore opportunities for collaboration, please contact email@example.com
About myeloproliferative neoplasms (MPN)
Myeloproliferative neoplasms (MPNs) are a group of rare blood cancers in which excess red blood cells, white blood cells, or platelets are produced in the bone marrow. Myelo refers to the bone marrow, proliferative describes the rapid growth of blood cells and neoplasm describes that growth as abnormal and uncontrolled.
About the MPN Hub
The MPN Hub is an open-access online resource, dedicated to providing balanced, credible, and up-to-date medical education in MPN. Our aim is to enhance knowledge of MPN through the multichannel dissemination of global advances related to their classification, diagnosis, treatment, and management.
The MPN Hub is the solution for a time-stretched HCP to easily access impactful information that expedites learning and empowers their treatment decisions. Informed by patients, curated by world leaders and endorsed by expert societies the MPN Hub supports HCPs worldwide.
The MPN Hub shares new data, evidence-based articles, therapy approvals, expert opinions, and international congress coverage to treatment teams and researchers around the world.
Funding for our hubs are made possible through financial support from the pharmaceutical industry. All content is developed by SES in collaboration with an expert Steering Committee.All content is independent, and the educational supporters are allowed no influence on the content.
- Bristol Myers Squibb
- Kartos Therapeutics
- Roche Genentech
- AOP Orphan
- Sierra Oncology
The MPN Hub would like to thank its supporters—Bristol Myers Squibb, Novartis, Kartos Therapeutics, Roche Genentech, AOP Orphan, Geron, and Sierra Oncology—for their continued support of the platform.
If you are interested in becoming an MPN supporter, please contact firstname.lastname@example.org
About Scientific Education Support (SES)
SES is a medical education company with projects such as community physician education through our therapy hubs, community awareness and education through our ‘KNOW’ education initiatives, and academic researcher education through Entrepreneurs in Clinical Academia (ECA) programs.
Scientific Education Support already has a portfolio of successful websites supporting the advancement of medical education in the field of hemato-oncology, which includes the Lymphoma Hub, AML Hub, Multiple Myeloma Hub, GvHD Hub, ALL Hub, and MDS Hub.
About The European LeukemiaNet
The European LeukemiaNet cooperates with 220 participating centers in 44 countries, with more than 1,000 researchers and clinicians. The objective is to integrate about 120 leading leukemia trial groups (CML, AML, ALL, CLL, MDS, MPN), their interdisciplinary partner groups (diagnostics, treatment research, registry, guidelines), industry, and SMEs across Europe to form a network promoting cooperative research for curing leukemia.